Rate My Professor James McFadyen

James McFadyen, MD, PhD, serves as Adjunct Associate Professor and Senior Lecturer in the Faculty of Medicine, Nursing and Health Sciences at Monash University, with affiliation to the Australian Centre for Blood Diseases. He is a Consultant Haematologist at the Alfred Hospital in Melbourne, Research Fellow and Group Leader at the Baker Heart and Diabetes Institute, and holds positions within the Baker Department of Cardiometabolic Health at the University of Melbourne, including supervision of postgraduate students at both institutions. McFadyen's clinical and research interests are explicitly focused on thrombosis and haemostasis, including platelet biology, platelet functional assays, in vivo models of thrombosis, intravital imaging, and novel platelet-targeted therapeutics. He is supported by a National Health and Medical Research Council and National Heart Foundation Research Fellowship. Additionally, he contributes to clinical services such as the Clinical Thrombosis Service and the Ronald Sawers Haemophilia Centre at the Alfred Hospital.

McFadyen has earned notable awards, including the Mammen F. Eberhard Young Investigator Award (2018), commendations for the Scientific Medal from the Thrombosis and Haemostasis Society of Australia and New Zealand (2018, 2014, 2013), and Alfred Health Basic Physician Training Program Lecturer of the Year (2016). He serves as a council member and Vice President of the Thrombosis and Haemostasis Society of Australia and New Zealand. His influential publications include 'Inherited thrombophilias are associated with a higher risk of COVID-19–associated venous thromboembolism: a prospective population-based cohort study' (Circulation, 2022), 'The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications' (Circulation Research, 2020), 'Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets' (Nature Communications, 2018), 'Current and future antiplatelet therapies: emphasis on preserving haemostasis' (Nature Reviews Cardiology, 2018), 'Targeting activated platelets: a unique and potentially universal approach for cancer imaging' (Theranostics, 2017), and 'Neutrophil macroaggregates promote widespread pulmonary thrombosis after gut ischemia' (Science Translational Medicine, 2017). These contributions have advanced understanding of thrombotic risks in COVID-19, cancer, diabetes, and vaccine-induced conditions, impacting haematology and cardiovascular fields.